The failure of Novo Nordisk’s ziltivekimab in a pivotal clinical study has caused significant concern within the biotechnology sector, casting doubt on emerging strategies for treating cardiovascular conditions by targeting
Pharmaceutical
202Articles
New Sanofi chief executive Belén Garijo has stated that repairing the relationship between her company and development partner Regeneron Pharmaceuticals is now a priority objective for the pharmaceutical giant. During
Poolbeg Pharma PLC has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The clinical-stage biopharmaceutical company is
Thalia Therapeutics plc (AIM:THAT), the AIM-listed RNA therapeutics developer, has confirmed that its proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75 million fundraising represent a transformational milestone for the
Jefferies has reinstated coverage of GSK PLC with a buy recommendation and a price target of 2,500 pence, representing approximately 30 per cent upside from the closing price of 1,916.50
Futura Medical shares rose after encouraging early data for a topical female sexual health gel, opening a possible new development opportunity.
Thalia Therapeutics plc, the AIM-quoted RNA therapeutics developer, has described its proposed acquisition of Sanmirna Therapeutics alongside a £2.75 million oversubscribed fundraising as a transformational step forward. Shareholders are scheduled
The robust second quarter sales performance of Johnson and Johnson’s Spravato depression treatment has reinforced investment bank Jefferies’ view that psychedelic drug developers may be addressing a commercially viable market
Germany has approved higher pharmaceutical rebates, with AstraZeneca warning the measures could reduce investment, research and access to medicines.
AstraZeneca shares dropped after Wainua failed to reduce cardiovascular deaths and recurrent heart events in a late-stage trial, dragging on the FTSE 100.
The late stage results for Wainua, AstraZeneca’s cardiovascular hopeful, have unleashed a fresh wave of reassessment about the company’s strategy, its reliance on a few big bets, and the fragility
When a Swiss pharmaceutical giant agrees to pay up to $1.5 billion for a British biotech that is not yet selling a single medicine, the first instinct in London is
The recent resumption of negotiations between AstraZeneca and NHS England concerning the availability of the breast cancer drug Enhertu marks a potentially significant turning point for patients suffering from incurable
Poolbeg Pharma PLC, the clinical-stage biopharmaceutical company listed on AIM, has secured a European patent for its POLB 001 treatment targeting cytokine release syndrome induced by cancer immunotherapy. The European
In a landmark development for the realm of pharmacological treatments for obesity, the United Kingdom has recently witnessed the approval of the Wegovy pill, a breakthrough that could redefine the
In a significant development that could alter the landscape of British retail, the private equity owners of Boots, the renowned pharmacy chain, are reportedly in discussions for a sale valued
